Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 15/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.55 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31034527 | 0.94 | TAS2R14 (0.60) | TAS2R14PTGESTAS2R8CXCR3MEP1B | |
| SCHEMBL29671340 | 0.87 | APLNR (0.61) | TAS2R14PTGESTAS2R8CXCR3APLNR | |
| SCHEMBL29671236 | 0.84 | TAS2R14 (0.53) | TAS2R14PTGESTAS2R8CXCR3HDAC11 | |
| SCHEMBL29665682 | 0.83 | APLNR (0.54) | TAS2R14PTGESTAS2R8CXCR3APLNR | |
| SCHEMBL31034579 | 0.83 | HDAC6 (0.52) | TAS2R14PTGESTAS2R8CXCR3APLNR | |
| SCHEMBL29671265 | 0.82 | TAS2R14 (0.45) | TAS2R14HDAC8 | |
| SCHEMBL28762106 | 0.80 | TAS2R14 (0.53) | TAS2R14 | |
| SCHEMBL24472769 | 0.80 | HDAC6 (0.77) | TAS2R14CXCR3MEP1BHDAC11HDAC8 | |
| SCHEMBL31034592 | 0.80 | APLNR (0.52) | TAS2R14PTGESTAS2R8CXCR3APLNR | |
| SCHEMBL31034596 | 0.80 | APLNR (0.52) | TAS2R14PTGESTAS2R8CXCR3APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022106902-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | TAS2R14 3563/4885PTGES 762/4885TAS2R8 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.